CLINICAL TRIAL: VIROLOGIC AND IMMUNOLOGIC EFFECTS OF ADDING ABACAVIR TO HIV PATI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目标如下： 1)(病毒学)确定阿巴卡韦的加入是否降低了用依地那韦和依法韦仑实现病毒抑制的受试者的病毒复制； 2)(病毒学)估算加入阿巴卡韦后游离病毒的衰减率； 3)(免疫学)对持续病毒抑制4年的患者队列中的HIV免疫反应进行表征； 4)(免疫学)确定在使用阿巴卡韦加强抗逆转录病毒治疗时，是否观察到艾滋病毒免疫反应增强和/或放大。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are as follows: 1) (Virologic) to determine if the addition of abacavir decreases viral replication in subjects with viral suppression achieved with indinavir and efavirenz; 2) (Virologic) to estimate the decay rate of free virus after the addition of abacavir; 3) (Immunologic) to characterize HIV immune responses in a cohort of patients with sustained viral suppression for 4 years; 4) (Immunologic) to determine if increased and/or amplified HIV immune responses are observed when antiretroviral therapy is augmented with abacavir.